ReviR Therapeutics is exploring a novel approach to regulate mutant AR and is developing small molecules to reduce its harmful effects.
Reward Amount $99,500. Mary McMahon, PhD - Director of Biology at ReviR Therapeutics.
Summary Description
Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy's disease, is a progressive neuromuscular disorder triggered by an expansion of a CAG repeat within the androgen receptor (AR) gene. ReviR Therapeutics is exploring a novel approach to regulate mutant AR and is developing small molecules to reduce its harmful effects.
Funded by the KDA, ReviR will develop and test these innovative small molecules to assess their impact on mutant AR expression in SBMA models. If successful, this project could lead to a groundbreaking therapy for individuals with SBMA.
Bio
Dr. Mary McMahon, PhD is the Director of Biology at ReviR Therapeutics, a biotechnology company pioneering innovative small-molecule RNA modulators. These treatments are designed to target neurogenetic diseases and previously “undruggable” conditions.
After earning her PhD from University College Cork, Ireland, and completing postdoctoral research at the University of California, San Francisco, Dr. McMahon delved into the molecular mechanisms behind age-related diseases like neurodegenerative disorders. Her research centered on the role of RNA processing and protein synthesis in these conditions.
At ReviR Therapeutics, Dr. McMahon is at the forefront of developing novel therapies for repeat expansion disorders such as Kennedy’s disease and Huntington’s disease.
